Matching articles for "Abilify MyCite"
Lumateperone (Caplyta) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • July 27, 2020; (Issue 1603)
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation...
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation antipsychotic
drug to be approved by the FDA for this indication.
Aripiprazole with Digital Ingestion Tracking (Abilify MyCite)
The Medical Letter on Drugs and Therapeutics • January 28, 2019; (Issue 1564)
Monitoring adherence of psychiatric patients to
oral medication may be especially difficult. The
FDA has approved Abilify MyCite (Otsuka/Proteus),
an aripiprazole tablet with an embedded sensor
that tracks...
Monitoring adherence of psychiatric patients to
oral medication may be especially difficult. The
FDA has approved Abilify MyCite (Otsuka/Proteus),
an aripiprazole tablet with an embedded sensor
that tracks when patients take the medication. It is
indicated for treatment of adults with schizophrenia,
bipolar disorder, or major depressive disorder. Abilify MyCite is the first drug with a digital ingestion tracking
system to be approved in the US.